This hypothesis is supported by non-clinical studies showing that gedatolisib was equally effective in breast cancer cell lines regardless of PIK3CA mutational status, while alpelisib (targeting only PI3Kα) and capivasertib (targeting only AKT) were less potent and efficacious in breast cancer cell lines with wild-type PIK3CA versus mutant PIK3CA [39]. This evidence concerns the gene PIK3CA and breast cancer.